Evaluation of the pharmacological descriptors related to the induction of antidepressant activity and its prediction by QSAR/QRAR methods

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 6, 2012, Pages 467-476

  Avram, S ^a   Buiu, C ^a,b   Duda Seiman, D ^c   Duda Seiman, C ^d   Borcan, F ^c   Mihailescu, D ^a  

^a UNIVERSITY OF BUCHAREST   (Romania)

^b UNIVERSITY POLITEHNICA OF BUCHAREST   (Romania)

^c VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d WEST UNIVERSITY OF TIMISOARA   (Romania)

Author keywords

Antidepressants; Drug design; Membrane receptors; Pharmaceutical descriptors; QRAR; QSAR

Indexed keywords

ADRENALIN; AMFEBUTAMONE; AMITRIPTYLINE; DESVENLAFAXINE; DOPAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1B AGONIST; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; VENLAFAXINE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CHEMISTRY; CHROMATOGRAPHY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC 50; LIGAND BINDING; MAJOR DEPRESSION; MELANCHOLIA; META ANALYSIS (TOPIC); MORTALITY; PHARMACOKINETICS; PUBLIC HEALTH PROBLEM; QUANTITATIVE RETENTION ACTIVITY RELATIONSHIP; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATIC ELECTRICITY;

EID: 84861143815     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712800493834     Document Type: Article

References (85)

1. Belmaker, R.H.; Agam G. Mechanisms of disease: Major depressive disorder. N Engl J Med., 2008, 358, 55-68.
2. th ed.; APA: Washington DC, 1994.
3. Spigset, O.; Mårtensson B. Drug treatment of depression. BMJ., 1999, 318, 1188-1191.
4. Sullivan, P.F.; Neale, M.C.; Kendler, K.S. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry, 2000, 157, 1552-1562.
5. Mann, J.J. The medical management of depression. N Engl J Med., 2005, 353, 1819-1834.
6. rd ed.; 2010.
7. Jiang, W.; Krishnan, R.R.; O'Connor, C.M. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs, 2002, 16, 111-127.
8. Paz-Filho, G., Licinio, J., Wong, M.L. Pathophysiological basis of cardiovascular disease and depression: a chicken-and-egg dilemma. Revista Brasileira de Psiquiatria, 2010, 32, 181-191.
9. Shelton, R.C. Classification of antidepressants and their clinical implications. Primary Care Companion J Clin Psychiatry, 2003, 5[suppl 7], 27-32.
10. Perović, B.; Jovanović, M.; Miljković, B.; Vezmar, S. Getting the balance right: established and emerging therapies for major depressive disorders. Neuropsychiatric Disease and Treatment, 2010, 6, 343-364.
11. Parker, G., Mitchell, P., Wilhelm, K., Menkes, D., Snowdon, J., Schweitzer, I., Grounds, D., Skerritt, P., Roy, K., Hadzi-Pavlovic, D. Are the new antidepressant drugs as effective as established physical treatments? Results from an Australian clinical panel review. Australian and New Zeeland Journal of Psychiatry, 1999, 33, 874-881.
12. Parker, G. 'New' and 'old' antidepressants: all equal in the eyes of the lore? British Journal of Psychiatry, 2001, 179, 95-96.
13. Williams, J.W.; Mulrow, C.D.; Chiquette, E.; Noël, P.; Aguilar, C.; Cornell, J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Clinical Guideline, Part 2. Ann Intern Med, 2000, 132(9), 743-756.
14. Arroll, B.; Macgillivray, S.; Ogston, S.; Reid, I.; Sullivan, F.; Williams, B.; Crombie, I. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med, 2005, 3, 449-456.
15. Anderson, I.M. Meta-analytical studies on new antidepressants. British Medical Bulletin, 2001, 57, 161-178.
16. Gartlehner, G.; Gaynes, B.N.; Hansen, R.A.; Thleda, P.; De Veaugh-Gelss, A.; Krebs, E.E.; Moore, C.G.; Morgan, L.; Lohr, K.N. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Clinical Guidelines. Ann Intern Med, 2008, 149, 734-750.
17. Quaseem, A.; Snow, V.; Denberg, T.D.; Forciea, M.A.; Owens, D.K. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med., 2008, 149(10), 725-733.
18. Gartlehner, G.; Gaynes, B.N. Are all antidepressants equal? Evid Based Mental Health, 2009, 12, 98-100.
19. Almeida, O.P.; Alfonso, H.; Hankey, G.J.; Flicker, L. Depression, antidepressant use and mortality in later life: The Health in Men Study. PLoS ONE, 2010, 5(6), e11266.
20. Pigott, H.E.; Leventhal, A.M.; Alter, G.S.; Boren, J.J. Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom., 2010, 79, 267-279.
21. Campiani, G.; Butini, S.; Fattorusso, C.; Trotta, F.; Gemma, S.; Catalanotti, B.; Nacci, V.; Fiorini, I.; Cagnotto, A.; Mereghetti, I.; Mennini, T.; Minetti, P.; Di Cesare, M. A.; Stasi, M. A.; Di Serio, S.; Ghirardi, O.; Tinti, O.; Carminati, P. Novel atypical antipsychotic agents: rational design, an efficient palladiumcatalyzed route, and pharmacological studies. J. Med. Chem., 2005, 48, 1705-1708.
22. Campiani, G.; Butini, S.; Fattorusso, C.; Catalanotti, B.; Gemma, S.; Nacci, V.; Morelli, E.; Cagnotto, A.; Mereghetti, I.; Mennini, T.; Carli, M.; Minetti, P.; Di Cesare, M. A.; Mastroianni, D.; Scafetta, N.; Galletti, B.; Stasi, M. A.; Castorina, M.; Pacifici, L.; Vertechy, M.; Di Serio, S.; Ghirardi, O.; Tinti, O.; Carminati, P. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. J. Med. Chem., 2004, 47, 143-157.
23. Campiani, G.; Butini, S.; Gemma, S.; Nacci, V.; Fattorusso, C.; Catalanotti, B.; Giorgi, G.; Cagnotto, A.; Goegan, M.; Mennini, T.; Minetti, P.; Di Cesare, M. A.; Mastroianni, D.; Scafetta, N.; Galletti, B.; Stasi, M. A.; Castorina, M.; Pacifici, L.; Ghirardi, O.; Tinti, O.; Carminati, P. Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. J. Med. Chem., 2002, 45, 344-359.
24. Nilsson, J.; Wikstrom, H.; Smilde, A.; Glase, S.; Pugsley, T.; Cruciani, G.; Pastor, M.; Clementi, S. GRID/GOLPE 3D quantitative structure-activity relationship study on a set of benzamides and naphthamides, with affinity for the dopamine D3 receptor subtype. J. Med. Chem., 1997, 40, 833-840.
25. Balle, T.; Andersen, K.; Soby, K. K.; Liljefors, T. Alpha(1) adrenoceptor subtype selectivity. 3D-QSAR models for a new class of alpha(1) adrenoceptor antagonists derived from the novel antipsychotic sertindole. J. Mol. Graph. Model., 2003, 21, 523-534.
26. Lanig, H.; Utz, W.; Gmeiner, P. Comparative molecular field analysis of dopamine D4 receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine. J. Med. Chem., 2001, 44, 1151-1157.
27. Bostrom, J.; Bohm, M.; Gundertofte, K.; Klebe, G. A 3D QSAR study on a set of dopamine D4 receptor antagonists. J. Chem. Inf. Comput. Sci., 2003, 43, 1020-1027.
28. Bostrom, J.; Gundertofte, K.; Liljeforsa, T. A pharmacophore model for dopamine D4 receptor antagonists. J. Comput. Aided. Mol. Des., 2000, 14, 769-786.
29. Audouze, K.; Nielsen, E. O.; Peters, D. New series of morpholine and 1,4-oxazepane derivatives as dopamine D4 receptor ligands: synthesis and 3D-QSAR model. J. Med. Chem., 2004, 47, 3089-3104.
30. Tehan, B. G.; Lloyd, E. J.; Wong, M. G. Molecular field analysis of clozapine analogs in the development of a pharmacophore model of antipsychotic drug action. J. Mol. Graph. Model., 2001, 19, 417-426.
31. Ravina, E.; Negreira, J.; Cid, J.; Masaguer, C. P.; Rosa, E.; Rivas, M. E.; Fontenla, J. A.; Loza, M. I.; Tristan, H.; Cadavid, M. I.; Sanz, F.; Lozoya, E.; Carotti, A.; Carrieri, A. Conformationally constrained butyrophenones with mixed dopaminergic (D(2) and serotoninergic (5-HT(2A), 5-HT(2C) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo-and-thienocycloalkanones as putative atypical antipsychotics. J. Med. Chem., 1999, 42, 2774-2797.
32. Schellander, R.; Donnerer, J. Antidepressants: Clinically Relevant Drug Interactions to Be Considered. Pharmacology. 2010, 86(4), 203-215.
33. Neri, S.; Bertino, G.; Petralia, A.; Giancarlo, C.; Rizzotto, A.; Calvagno, G.S.; Mauceri, B.; Abate, G.; Boemi, P.; Di Pino, A.; Ignaccolo, L.; Vadalà, G.; Misseri, M.; Maiorca, D.; Mastrosimone, G.; Judica, A.; Palermo, F. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. J Clin Gastroenterol., 2010, 44(9), e210-217.
34. Haskett, R.F.; Loo, C. Adjunctive psychotropic medications during electroconvulsive therapy in the treatment of depression, mania, and schizophrenia. J ECT., 2010, 26(3), 196-201.
35. Macgillivray, L.; Lagrou, L.M.; Reynolds, K.B.; Rosebush, P.I.; Mazurek, M.F. Role of serotonin transporter inhibition in the regulation of tryptophan hydroxylase in brainstem raphe nuclei: time course and regional specificity. Neuroscience, 2010, 171(2), 407-420.
36. Hajjo, R.; Grulke, C.M.; Golbraikh, A.; Setola, V.; Huang, X.P.; Roth, B.L.; Tropsha, A. Development, Validation, and Use of Quantitative Structure-Activity Relationship Models of 5-Hydroxytryptamine (2B) Receptor Ligands to Identify Novel Receptor Binders and Putative Valvulopathic Compounds among Common Drugs. J Med Chem., 2010, 53(21), 7573-7586.
37. Brea, J.; Rodrigo, J.; Carrieri, A.; Sanz, F.; Cadavid, M.I.; Enguix, M.J.; Villazón, M.; Mengod, G.; Caro, Y.; Masaguer, C.F.; Raviña, E.; Centeno, N.B.; Carotti, A.; Loza, M.I. New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones. Med Chem., 2002, 45(1), 54-71.
38. Jesse, C.R.; Wilhelm, E.A.; Bortolatto, C.F.; Nogueira, C.W. Evidence for the involvement of the noradrenergic system, dopaminergic and imidazoline receptors in the antidepressant-like effect of tramadol in mice. Pharmacol Biochem Behav., 2010, 95(3), 344-350.
39. Manta, S.; Dong, J.; Debonnel, G.; Blier, P. Enhancement of the function of rat serotonin and norepinephrine neurons by sustained vagus nerve stimulation. J Psychiatry Neurosci., 2009, 34(4), 272-280.
40. Jhaveri, D.J.; Mackay, E.W.; Hamlin, A.S.; Marathe, S.V.; Nandam, L.S.; Vaidya, V.A.; Bartlett, P.F. Norepinephrine directly activates adult hippocampal precursors via beta3-adrenergic receptors. J Neurosci., 2010, 30(7), 2795-2806.
41. López, L.; Selent, J.; Ortega, R.; Masaguer, C.F.; Domínguez, E.; Areias, F.; Brea, J.; Loza, M.I.; Sanz, F.; Pastor, M. Synthesis, 3DQSAR, and structural modeling of benzolactam derivatives with binding affinity for the D(2) and D(3) receptors. Med Chem., 2010, 5(8), 1300-1317.
42. de Graaf, C.; Foata, N.; Engkvist, O.; Rognan, D. Molecular modeling of the second extracellular loop of G-protein coupled receptors and its implication on structure-based virtual screening. Proteins, 2008, 71(2), 599-620.
43. 2 receptor and its testing by docking of agonists and tricyclic antagonists. J. Med. Chem., 1994, 37, 2874-2888.
44. Andrade, C.H.; Salum, L.B.; Pasqualoto, K.F.M.; Ferreir, E.I.; Andricopulo, A.D. Three-Dimensional Quantitative Structure-Activity Relationships for a Large Series of Potent Antitubercular Agents. Lett. Drug Des. Discov., 2008, 5, 377-387.
45. Akamatsu, M. Current state and perspectives of 3D-QSAR. Curr. Top. Med. Chem., 2002, 2, 1381-1394.
46. Frederic, C.; Cristine Ada, C.; Erwan, A.; David, A.; Cecile, D.; Michael, F.; Jean-Francois, H.; Martinez, J.; Solveig, L.J.; Philippe, M.; Andrea, P.; Agnes, P.; Christopher, P.; Philippe, R.; Peter, S.G.; Sherwin, W. JLK inhibitors: isocoumarin compounds as putative probes to selectively target the gamma-secretase pathway. Curr. Alzheimer Res., 2005, 2, 327-334.
47. Garg, A.; Tewari, R.; Raghava, G.P. KiDoQ: using docking based energy scores to develop ligand based model for predicting antibacterials. BMC Bioinformatics, 2010, 11, 125.
48. Gundersen, E.; Fan, K.; Haas, K.; Huryn, D.; Steven Jacobsen, J.; Kreft, A.; Martone, R.; Mayer, S.; Sonnenberg-Reines, J.; Sun, S.C.; Zhou, H. Molecular-modeling based design, synthesis, and activity of substituted piperidines as gamma-secretase inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 1891-1894.
49. Prasad, C.V.; Vig, S.; Smith, D.W.; Gao, Q.; Polson, C.T.; Corsa, J.A.; Guss, V.L.; Loo, A.; Barten, D.M.; Zheng, M.; Felsenstein, K.M.; Roberts, S.B. 2,3-Benzodiazepin-1,4-diones as peptidomimetic inhibitors of gamma-secretase. Bioorg. Med. Chem. Lett., 2004, 14, 3535-3538.
50. Park, H.; Lee, S. Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. J. Am. Chem. Soc., 2003, 125, 16416-16422.
51. Hu, J.; Cwi, C.L.; Smiley, D.L.; Timm, D.; Erickson, J.A.; McGee, J.E.; Yang, H.C.; Mendel, D.; May, P.C.; Shapiro, M.; McCarthy, J.R. Design and synthesis of statine-containing BACE inhibitors. Bioorg. Med. Chem. Lett., 2003, 13, 4335-4339.
52. Ghosh, A.K.; Devasamudram, T.; Hong, L.; DeZutter, C.; Xu, X.; Weerasena, V.; Koelsch, G.; Bilcer, G.; Tang, J. Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase). Bioorg. Med. Chem. Lett., 2005, 15, 15-20.
53. Snyder, R.D.; Hendry, L.B. Toward a greater appreciation of noncovalent chemical/DNA interactions: application of biological and computational approaches. Environ. Mol. Mutagen., 2005, 45, 100-105.
54. Zuo, Z.; Luo, X.; Zhu, W.; Shen, J.; Shen, X.; Jiang, H.; Chen, K. Molecular docking and 3D-QSAR studies on the binding mechanism of statine-based peptidomimetics with beta-secretase. Bioorg. Med. Chem., 2005, 13, 2121-2131.
55. Hayashi, Y.; Sakaguchi, K.; Kobayashi, M.; Kikuchi, Y.; Ichiishi, E. Molecular evaluation using in silico protein interaction profiles. Bioinformatics, 2003, 19, 1514-1523.
56. Oprea, T.I.; Waller, C.L.; Marshall, G.R. Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes. J. Med. Chem., 1994, 37, 2206-2215.
57. Chemical Computing Group. http://www.chemcomp.com (Accessed November 13, 2010).
58. Sybyl Basic Ligand-Based Design Manual, Tripos Associates Inc.: St. Louis, 1988.
59. The Laboratory for Molecular Simulation. http://lms.chem. tamu.edu/cerius2.html (Accessed November 13, 2010).
60. Avram, S.; Berner, H.; Milac, A.L.; Wolschann, P. Quantitative structure-activity relationship studies on membrane receptors inhibition by antipsychotic drugs. Application to new schizophrenia. Chemical Monthly, 2008, 139, 407.
61. Catana, C.; Gao, H.; Orrenius, C.; Stouten P.F.W. Linear and nonlinear methods in modeling the aqueous solubility of organic compounds. J. Chem. Inf. Model., 2005, 45, 170-176.
62. Kier, L.B.; Hall, L.H. Intermolecular accessibility: the meaning of molecular connectivity. J. Chem. Inf. Comput. Sci., 2000, 40, 792-795.
63. Kier, L.B. Inclusion of symmetry as a shape attribute in kappaindex analysis. Quant. Struct-Act. Relat., 1987, 6, 8-12.
64. Petitjean, M. Applications of the radius-diameter diagram to the classification of topological and geometrical shapes of chemical compounds. J. Chem. Inf. Comput. Sci., 1992, 32, 331-337
65. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron, 1980, 36, 3219-3228.
66. Stanton, D.; Jurs, P. Development and use of the charged partial surface area structural descriptors in computer-assisted quantitative structure-property relationship studies. Anal. Chem., 1990, 62, 2323-2329.
67. Cramer, R.D. 3rd; Patterson, D.E.; Bunce, J.D. Recent advances in comparative molecular field analysis (CoMFA). Prog. Clin. Biol. Res., 1989, 291, 161-165.
68. Khedkar, S.A.; Malde, A.K.; Coutinho, E.C. CoMFA study of distamycin analogs binding to the minor-groove of DNA: a unified model for broad-spectrum activity. J Mol Model., 2007, 13(10), 1099-1108.
69. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem., 1994, 37, 4130-4146.
70. Carosati, E.; Lemoine, H.; Spogli, R.; Grittner, D.; Mannhold, R.; Tabarrini, O.; Sabatini, S.; Cecchetti, V. Binding studies and GRIND/ALMOND-based 3D QSAR analysis of benzothiazine type K(ATP)-channel openers. Bioorg. Med. Chem., 2005, 13, 5581-5591.
71. Clark, D.E. Prediction of Intestinal Absorption and Blood-Brain Barrier Penetration by Computational Methods. Comb. Chem. High Throughput Screen, 2001, 4, 477-496.
72. Quiñones-Torrelo, C.; Sagrado, S.; Villanueva-Camañas, R.M.; Medina-Hernández, M.J. Development of predictive retentionactivity relationship models of tricyclic antidepressants by micellar liquid chromatography, J Med Chem., 1999, 42(16), 3154-3162.
73. Wang, S.R.; Chen, Y.; Wu, L.P.; Miao, W.J.; Xiong, M.J.; Chen, C.; Zhong, Z.R.; Ye, L.M. Development of predictive quantitative retention-activity relationship models of HMG-CoA reductase inhibitors by biopartitioning micellar chromatography, J Pharm Biomed Anal., 2008, 46(2), 243-249.
74. Wang, S.R.; Chen, Y.; Xiong, M.J.; Wu, L.P.; Ye, L.M. Quantitative retention-activity relationship models of angiotensin converting enzyme inhibitors using biopartitioning micellar chromatography, J Chromatogr Sci.,2010, 48(2), 134-139.
75. Pidgeon, C.; Ong, S.; Liu, H.; Qiu, X.; Pidgeon, M.; Dantzig, A.H.; Munroe, J.; Hornback, W.J.; Kasher, J.S.; Glunz, L.; Szczerba, T. IAM chromatography: an in vitro screen for predicting drug membrane permeability. J. Med. Chem., 1995, 38, 590-594.
76. Balon, K.; Riebesehl, B.U., Muller, B.W. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption. Pharm. Res., 1999, 16, 882-888.
77. Lundqvist, A.; Lundahl, P. Chromatography on Cells and Biomolecular Assemblies. J. Chromatogr. B 1997, 699, 209-220.
78. Berthod, A.; Girard, I.; Gomet, C. Micellar Liquid Chromatography. Adsorption Isotherms of Two Ioninc Surfactants on Five Stationary Phases. Anal. Chem., 1986, 58, 1356-1358.
79. Avram, S.; Buiu, C.; Duda-Seiman, D.M.; Duda-Seiman, C.; Mihailescu, D. Design of new escitalopram derivatives for the treatment of major depressive disorder by 3D-QSAR, Sci Pharm., 2010, 78, 233-248.
80. Chen, K.X.; Li, Z.G.; Xie, H.Y.; Gao, J.R.; Zou, J.W. Quantitative structure-activity relationship analysis of aryl alkanol piperazine derivatives with antidepressant activities. Eur J Med Chem., 2009, 44(11), 4367-4375.
81. Shelke, S. M; Bhosale, S.H. Synthesis, antidepressant evaluation and QSAR studies of novel 2-(5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)-N-(substituted phenyl)acetamides. Bioorganic & Medicinal Chemistry Letters, 2010, 20(15), 4661-4664.
82. Weber, K.C.; Honório, K.M.; Andricopulo, A.D.; Da Silva, A.B. Two-dimensional QSAR studies on arylpiperazines as high-affinity 5-HT(1A) receptor ligands. Med Chem., 2008, 4(4), 328-335.
83. 1A receptor ligands. European Journal of Medicinal Chemistry, 2010, 45(4), 1508-1514.
84. 1A receptor affinities presented by arylpiperazine compounds. European Journal of Medicinal Chemistry, 2008, 43(2), 364-372.
85. Dessalew, N. QSAR Study on Dual 5-HT1Aand 5-HT1B Antagonists: An Insight into the Structural Requirement for Antidepressant Activity. Arch. Pharm. Chem. Life Sci., 2008, 341, 314-322.